DK2081551T3 - Formation of a dried reconstituted vesicle for pharmaceutical use - Google Patents

Formation of a dried reconstituted vesicle for pharmaceutical use

Info

Publication number: DK2081551T3
Authority: DK; Denmark
Prior art keywords: formation; pharmaceutical use; dried reconstituted; vesicle; reconstituted vesicle
Prior art date: 2006-10-06

Application number

DK07818735.8T

Other languages

Danish (da)

Inventor

Klaus Hellerbrand

Andreas Schuetz

Rainer Sigl

Original Assignee

Scil Technology Gmbh

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2006-10-06

Filing date

2007-10-05

Publication date

2013-05-06

2007-10-05 Application filed by Scil Technology Gmbh filed Critical Scil Technology Gmbh

2013-05-06 Application granted granted Critical

2013-05-06 Publication of DK2081551T3 publication Critical patent/DK2081551T3/en

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/1875—Bone morphogenic factor; Osteogenins; Osteogenic factor; Bone-inducing factor
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/35—Fat tissue; Adipocytes; Stromal cells; Connective tissues
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0085—Brain, e.g. brain implants; Spinal cord
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Liposomes
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Liposomes
- A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers
- A61K9/1272—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers with substantial amounts of non-phosphatidyl, i.e. non-acylglycerophosphate, surfactants as bilayer-forming substances, e.g. cationic lipids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Veterinary Medicine (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Engineering & Computer Science (AREA)
Epidemiology (AREA)
Bioinformatics & Cheminformatics (AREA)
Immunology (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Organic Chemistry (AREA)
Biomedical Technology (AREA)
Orthopedic Medicine & Surgery (AREA)
Zoology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Dispersion Chemistry (AREA)
Gastroenterology & Hepatology (AREA)
Physical Education & Sports Medicine (AREA)
Rheumatology (AREA)
Psychology (AREA)
Cell Biology (AREA)
Molecular Biology (AREA)
Biophysics (AREA)
Dermatology (AREA)
Biotechnology (AREA)
Virology (AREA)
Developmental Biology & Embryology (AREA)
Hospice & Palliative Care (AREA)
Pain & Pain Management (AREA)
Psychiatry (AREA)
Oil, Petroleum & Natural Gas (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

DK07818735.8T 2006-10-06 2007-10-05 Formation of a dried reconstituted vesicle for pharmaceutical use DK2081551T3 (en)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
EP06021093		2006-10-06
PCT/EP2007/008659 WO2008040556A1 (en)	2006-10-06	2007-10-05	Dried reconstituted vesicle formation for pharmaceutical application

Publications (1)

Publication Number	Publication Date
DK2081551T3 true DK2081551T3 (en)	2013-05-06

Family

ID=38910893

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
DK07818735.8T DK2081551T3 (en)	2006-10-06	2007-10-05	Formation of a dried reconstituted vesicle for pharmaceutical use

Country Status (17)

Country	Link
US (3)	US9526761B2 (en)
EP (2)	EP2081551B1 (en)
JP (2)	JP5484059B2 (en)
KR (1)	KR101333279B1 (en)
CN (3)	CN101528197B (en)
CA (1)	CA2664637C (en)
CY (1)	CY1113934T1 (en)
DK (1)	DK2081551T3 (en)
ES (2)	ES2708851T3 (en)
HR (1)	HRP20130328T1 (en)
PL (1)	PL2081551T3 (en)
PT (1)	PT2081551E (en)
RS (1)	RS52706B (en)
RU (1)	RU2443412C2 (en)
SI (1)	SI2081551T1 (en)
TW (1)	TWI455731B (en)
WO (2)	WO2008040556A1 (en)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6907884B2 (en)	2002-09-30	2005-06-21	Depay Acromed, Inc.	Method of straddling an intraosseous nerve
US8361067B2 (en)	2002-09-30	2013-01-29	Relievant Medsystems, Inc.	Methods of therapeutically heating a vertebral body to treat back pain
US7258690B2 (en)	2003-03-28	2007-08-21	Relievant Medsystems, Inc.	Windowed thermal ablation probe
US7879103B2 (en)	2005-04-15	2011-02-01	Musculoskeletal Transplant Foundation	Vertebral disc repair
WO2008013763A2 (en)	2006-07-25	2008-01-31	Musculoskeletal Transplant Foundation	Packed demineralized cancellous tissue forms for disc nucleus augmentation, restoration, or replacement and methods of implantation
US10028753B2 (en)	2008-09-26	2018-07-24	Relievant Medsystems, Inc.	Spine treatment kits
JP5688022B2 (en)	2008-09-26	2015-03-25	リリーバントメドシステムズ、インコーポレイテッド	System and method for guiding an instrument through the interior of a bone
AU2011247659B2 (en) *	2010-04-27	2014-07-24	Scil Technology Gmbh	Stable aqueous MIA/CD-RAP formulations
AU2012362524B2 (en)	2011-12-30	2018-12-13	Relievant Medsystems, Inc.	Systems and methods for treating back pain
US20130202682A1 (en) *	2012-01-24	2013-08-08	The Trustees Of Columbia University In The City Of New York	Synthetic matrix vesicles for biomimetic mineralization
NZ703532A (en) *	2012-07-05	2018-02-23	Taiwan Liposome Co Ltd	Methods of treating arthritis
US10588691B2 (en)	2012-09-12	2020-03-17	Relievant Medsystems, Inc.	Radiofrequency ablation of tissue within a vertebral body
IL238516B (en)	2012-11-05	2022-08-01	Relievant Medsystems Inc	System and methods for creating curved paths through bone and modulating nerves within the bone
US9724151B2 (en)	2013-08-08	2017-08-08	Relievant Medsystems, Inc.	Modulating nerves within bone using bone fasteners
US8986732B2 (en)	2013-08-12	2015-03-24	Helix Biopharma Corporation	Biphasic lipid-vesicle compositions and methods for treating cervical dysplasia by intravaginal delivery
US10159646B2 (en) *	2013-08-12	2018-12-25	Altum-Avro Pharma Partnership	Biphasic lipid-vesicle compositions and methods for treating cervical dysplasia by intravaginal delivery
BR112017011258B1 (en) *	2014-12-18	2024-02-06	Bracco Suisse S.A	AQUEOUS SUSPENSION OF MICROVESCLES FILLED WITH GAS AND PHARMACEUTICAL KIT
US11376218B2 (en)	2015-05-04	2022-07-05	Versantis AG	Method for preparing transmembrane pH-gradient vesicles
AU2016321884B2 (en) *	2015-09-18	2021-01-07	Bionet Pharma Gmbh	Improvement of expression and folding in the manufacturing process of CD-RAP by using a CD-RAP precursor protein
CA3019751A1 (en) *	2016-04-04	2017-10-12	Gu Ventures Ab	Methods and compositions for the treatment of intervertebral disc herniation
EP3618836A4 (en) *	2017-04-25	2021-01-13	Adjuvance Technologies, Inc.	Triterpene saponin analogues
PT3675816T (en) *	2017-08-28	2023-05-31	Taiwan Liposome Co Ltd	Sustained-release anesthetic compositions and methods of preparation thereof
US11389405B2 (en)	2017-09-18	2022-07-19	North Carolina State University	Artificial beta cells and methods of use thereof
KR102649069B1 (en)	2018-05-31	2024-03-19	주식회사 엑소코바이오	Composition for improving face redness comprising an exosome derived from stem cell as an active ingredient
KR102058961B1 (en)	2018-07-28	2019-12-24	주식회사 엑소코바이오	Method for freeze-drying exosomes
KR102163806B1 (en) *	2018-07-30	2020-10-07	주식회사 엑소코바이오	Composition for reducing sebum release comprising an exosome derived from stem cell as an active ingredient
RS65449B1 (en) *	2018-10-09	2024-05-31	Univ British Columbia	Compositions and systems comprising transfection-competent vesicles free of organic-solvents and detergents and methods related there to
AU2020346827A1 (en)	2019-09-12	2022-03-31	Relievant Medsystems, Inc.	Systems and methods for tissue modulation
US12082876B1 (en)	2020-09-28	2024-09-10	Relievant Medsystems, Inc.	Introducer drill
JP2024505335A (en)	2020-12-22	2024-02-06	リリーバントメドシステムズ、インコーポレイテッド	Prediction of spinal neuromodulation candidates
CN113995852B (en) *	2021-11-08	2024-01-30	河北大学	Arg-liposome microcapsule, microencapsulated protamine-siRNA complex, and preparation method and application thereof

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CH621479A5 (en) *	1977-08-05	1981-02-13	Battelle Memorial Institute
FR2416008A1 (en) *	1978-02-02	1979-08-31	Oreal	LIPOSOME LYOPHILISATES
IL79114A (en) *	1985-08-07	1990-09-17	Allergan Pharma	Method and composition for making liposomes
FR2591105B1 (en) *	1985-12-11	1989-03-24	Moet Hennessy Rech	PHARMACEUTICAL COMPOSITION, IN PARTICULAR DERMATOLOGICAL, OR COSMETIC, BASED ON HYDRATED LIPID LAMELLAR PHASES OR LIPOSOMES CONTAINING A RETINOIDE OR A STRUCTURAL ANALOG OF SUCH A RETINOID AS A CAROTENOID.
US4897353A (en) *	1986-03-13	1990-01-30	University Of Southwestern Louisiana	Cryogenic protection of phosphofructokinase using amino acids and zinc ions
US5709879A (en) *	1990-06-29	1998-01-20	Chiron Corporation	Vaccine compositions containing liposomes
AU8329391A (en) *	1990-08-08	1992-03-02	Liposome Technology, Inc.	Stable doxorubicin/liposome composition
CA2120197A1 (en) *	1993-04-02	1994-10-03	Kenji Endo	Stable aqueous dispersions containing liposomes
GB9320668D0 (en) *	1993-10-07	1993-11-24	Secr Defence	Liposomes containing particulare materials
US6066331A (en) *	1994-07-08	2000-05-23	Barenholz; Yechezkel	Method for preparation of vesicles loaded with biological structures, biopolymers and/or oligomers
IL115199A (en)	1995-09-07	2005-05-17	Opperbas Holding Bv	Composition comprising a polynucleic acid molecule in a liposome and method using said composition
US6287590B1 (en) *	1997-10-02	2001-09-11	Esperion Therapeutics, Inc.	Peptide/lipid complex formation by co-lyophilization
WO2000012762A1 (en) *	1998-09-01	2000-03-09	Millennium Pharmaceuticals, Inc.	A novel protein related to melanoma-inhibiting protein and uses thereof
EP1025871A1 (en) *	1999-01-28	2000-08-09	F. Hoffmann-La Roche Ag	Use of a melanoma inhibiting activity factor (MIA) for cartilage and bone repair
US7435260B2 (en) *	1999-08-13	2008-10-14	Ferree Bret A	Use of morphogenetic proteins to treat human disc disease
CA2392721C (en) *	1999-12-06	2009-01-20	Sdgi Holdings, Inc.	Intervertebral disc treatment devices and methods
EP1432403B1 (en) *	2001-10-03	2010-07-28	Celator Pharmaceuticals, Inc.	Liposome loading with metal ions
EP1513853A2 (en) *	2002-05-24	2005-03-16	Neopharm, Inc.	Cardiolipin compositions, methods of preparation and use
US7169405B2 (en) *	2003-08-06	2007-01-30	Warsaw Orthopedic, Inc.	Methods and devices for the treatment of intervertebral discs
GB2430368B (en) *	2004-03-30	2009-08-26	Ilypsa Inc	Methods and compositions for treatment of ion imbalances
ZA200610272B (en) *	2004-05-21	2008-07-30	Synthes Gmbh	Replacement of nucleus pulposus using a hydrogel
JP5201987B2 (en) *	2004-05-25	2013-06-05	ストライカーコーポレイション	Use of morphogenic proteins to treat cartilage defects
EP1604693A1 (en) *	2004-06-09	2005-12-14	Scil Technology GmbH	In situ forming scaffold, its manufacturing and use
JP2008518951A (en) *	2004-10-28	2008-06-05	アルザコーポレイション	Lyophilized liposome formulations and methods
US20110071056A1 (en) *	2009-09-24	2011-03-24	Rajesh K Saini	Degradable Surfactants, Including Degradable Gemini Surfactants, and Associated Methods

2007
- 2007-10-05 EP EP07818735A patent/EP2081551B1/en active Active
- 2007-10-05 PL PL07818735T patent/PL2081551T3/en unknown
- 2007-10-05 CN CN2007800397245A patent/CN101528197B/en not_active Expired - Fee Related
- 2007-10-05 CN CN2012104557068A patent/CN102940878A/en active Pending
- 2007-10-05 ES ES07818736T patent/ES2708851T3/en active Active
- 2007-10-05 CN CNA2007800422016A patent/CN101605534A/en active Pending
- 2007-10-05 DK DK07818735.8T patent/DK2081551T3/en active
- 2007-10-05 EP EP07818736.6A patent/EP2086507B1/en not_active Not-in-force
- 2007-10-05 WO PCT/EP2007/008659 patent/WO2008040556A1/en active Application Filing
- 2007-10-05 KR KR1020097009193A patent/KR101333279B1/en active IP Right Grant
- 2007-10-05 JP JP2009530811A patent/JP5484059B2/en not_active Expired - Fee Related
- 2007-10-05 SI SI200731193T patent/SI2081551T1/en unknown
- 2007-10-05 TW TW096137658A patent/TWI455731B/en not_active IP Right Cessation
- 2007-10-05 PT PT78187358T patent/PT2081551E/en unknown
- 2007-10-05 ES ES07818735T patent/ES2400162T3/en active Active
- 2007-10-05 JP JP2009530810A patent/JP5404402B2/en not_active Expired - Fee Related
- 2007-10-05 RS RS20130131A patent/RS52706B/en unknown
- 2007-10-05 WO PCT/EP2007/008660 patent/WO2008040557A1/en active Application Filing
- 2007-10-05 CA CA2664637A patent/CA2664637C/en not_active Expired - Fee Related
- 2007-10-05 RU RU2009117170/15A patent/RU2443412C2/en not_active IP Right Cessation
2009
- 2009-04-06 US US12/419,167 patent/US9526761B2/en not_active Expired - Fee Related
- 2009-04-06 US US12/419,131 patent/US20090297580A1/en not_active Abandoned
2013
- 2013-04-10 HR HRP20130328TT patent/HRP20130328T1/en unknown
- 2013-04-18 CY CY20131100316T patent/CY1113934T1/en unknown
2016
- 2016-03-08 US US15/064,444 patent/US20160220638A1/en not_active Abandoned

Also Published As

Publication number	Publication date
EP2081551B1 (en)	2013-01-23
ES2708851T3 (en)	2019-04-11
KR20090086397A (en)	2009-08-12
EP2081551A1 (en)	2009-07-29
CA2664637A1 (en)	2008-04-10
JP2010505482A (en)	2010-02-25
CY1113934T1 (en)	2016-07-27
JP5484059B2 (en)	2014-05-07
CN101605534A (en)	2009-12-16
JP2010505785A (en)	2010-02-25
HRP20130328T1 (en)	2013-05-31
TW200829283A (en)	2008-07-16
US20160220638A1 (en)	2016-08-04
US20090285880A1 (en)	2009-11-19
CN101528197A (en)	2009-09-09
CN102940878A (en)	2013-02-27
RU2443412C2 (en)	2012-02-27
TWI455731B (en)	2014-10-11
US20090297580A1 (en)	2009-12-03
WO2008040557A1 (en)	2008-04-10
WO2008040556A1 (en)	2008-04-10
EP2086507A1 (en)	2009-08-12
US9526761B2 (en)	2016-12-27
PL2081551T3 (en)	2013-06-28
CN101528197B (en)	2013-02-13
RS52706B (en)	2013-08-30
RU2009117170A (en)	2010-11-20
EP2086507B1 (en)	2018-11-07
CA2664637C (en)	2013-11-12
PT2081551E (en)	2013-02-18
JP5404402B2 (en)	2014-01-29
SI2081551T1 (en)	2013-05-31
ES2400162T3 (en)	2013-04-08
KR101333279B1 (en)	2013-11-27

Publication	Publication Date	Title
DK2081551T3 (en)	2013-05-06	Formation of a dried reconstituted vesicle for pharmaceutical use
LTC2004635I2 (en)	2021-05-25	Substituted enaminocarbonyl compounds
DK2041139T3 (en)	2012-01-16	Pharmaceutical compounds
DK2399579T3 (en)	2013-06-17	Pharmaceutical dosage forms
DK2094676T3 (en)	2013-06-10	NEW PROCEDURE FOR THE PREPARATION OF 2-IMINOTHIAZOLIDIN-4-ON DERIVATIVES
DK1981859T3 (en)	2013-01-21	PREPARATION OF DELMOPINOL
DK2016080T3 (en)	2010-11-22	Dihydropyrazolopyrimidinon derivatives
ATE483711T1 (en)	2010-10-15	SPIROINDOLINONE DERIVATIVES
BRPI0715712A2 (en)	2014-06-24	PHARMACEUTICAL COMPOSITION
ATE469905T1 (en)	2010-06-15	PYRIDOPYRIMIDINONE DERIVATIVES
DK1986650T3 (en)	2012-08-13	MANIPULATION-SAFE DOSAGE FORMS
BRPI0821831A2 (en)	2015-06-16	Insecticide Compounds
ATE512135T1 (en)	2011-06-15	SPIROINDOLINONE DERIVATIVES
DK2046767T3 (en)	2015-06-22	Process for the preparation of diaminophenothiazinium compounds
DK2035394T3 (en)	2009-10-05	2-pyrazinecarboxamide derivatives
BRPI0719393A2 (en)	2015-03-31	Pharmaceutical Composition
ATE524477T1 (en)	2011-09-15	AZIRIDINYLEPOTHILONE COMPOUNDS
BRPI0716445A2 (en)	2013-09-17	pharmaceutical composition
BRPI0720234A2 (en)	2013-12-24	PHARMACEUTICAL COMPOSITION
DK2018158T3 (en)	2013-07-22	New racecadotril administration form
DK2086968T3 (en)	2012-03-19	5-hydroxymethyl-oxazolidin-2-one derivatives
DE602007001593D1 (en)	2009-08-27	Aryl / ALKYLVINYLSULFON-HYALURONIC DERIVATIVES
DK2271618T3 (en)	2014-06-16	Pharmaceutical compounds
DK2131818T3 (en)	2014-05-26	NEW DOSAGE FORM
DK2143445T3 (en)	2013-11-25	Drug-prepared patch